Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase

Sébastien PYR DIT RUYS*1, Xuemin WANG†‡1, Ewan M. SMITH†2, Gaëtan HERINCKX*, Nusrat HUSSAIN*, Mark H. RIDER*, Didier VERTOMMEN* and Christopher G. PROUD†‡3 *Université catholique de Louvain and de Duve Institute, 75 Avenue Hippocrate, B-1200 Brussels, Belgium, †Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada, V6T 1Z3, and ‡Centre for Biological Sciences, Life Sciences Building, University of Southampton, Southampton SO17 1BJ, U.K.

[1]  S. Burchill,et al.  Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria , 2012, British Journal of Cancer.

[2]  C. Proud,et al.  Insights into the regulation of eukaryotic elongation factor 2 kinase and the interplay between its domains , 2011, The Biochemical journal.

[3]  J. Duley,et al.  Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited‐sampling, population modelling approach , 2011, Journal of paediatrics and child health.

[4]  B. Turk,et al.  Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. , 2011, Protein expression and purification.

[5]  Steven P. Smith,et al.  Identification of calmodulin and MlcC as light chains for Dictyostelium myosin-I isozymes. , 2011, Biochemistry.

[6]  T. Alain,et al.  Pharmacological and Genetic Evaluation of Proposed Roles of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK), Extracellular Signal-regulated Kinase (ERK), and p90RSK in the Control of mTORC1 Protein Signaling by Phorbol Esters* , 2011, The Journal of Biological Chemistry.

[7]  L. Runnels,et al.  TRPM6 and TRPM7: A Mul-TRP-PLIK-cation of channel functions. , 2011, Current pharmaceutical biotechnology.

[8]  J. Bonner.  Dictyostelium discoideum , 2011 .

[9]  Ora Schueler-Furman,et al.  Autophosphorylation Activates Dictyostelium Myosin II Heavy Chain Kinase A by Providing a Ligand for an Allosteric Binding Site in the α-Kinase Domain* , 2010, The Journal of Biological Chemistry.

[10]  Brian D. Marsden,et al.  High-throughput production of human proteins for crystallization: The SGC experience , 2010, Journal of structural biology.

[11]  Wen Hwa Lee,et al.  Structure of the CaMKIIδ/Calmodulin Complex Reveals the Molecular Mechanism of CaMKII Kinase Activation , 2010, PLoS biology.

[12]  Zongchao Jia,et al.  Crystal Structure of the α-Kinase Domain of Dictyostelium Myosin Heavy Chain Kinase A , 2010, Science Signaling.

[13]  Manolis Kellis,et al.  The Tasmanian Devil Transcriptome Reveals Schwann Cell Origins of a Clonally Transmissible Cancer , 2009, Science.

[14]  R. Pinkerton,et al.  Vincristine: Can its therapeutic index be enhanced? , 2009, Pediatric blood & cancer.

[15]  Shelly Lachish,et al.  Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction. , 2009, Ecology.

[16]  G. Mei,et al.  Monomer-dimer equilibrium in glutathione transferases: a critical re-examination. , 2009, Biochemistry.

[17]  S. W. Crawley,et al.  Identification of dimer interactions required for the catalytic activity of the TRPM7 alpha-kinase domain. , 2009, The Biochemical journal.

[18]  Menna E. Jones,et al.  Demography, disease and the devil: life-history changes in a disease-affected population of Tasmanian devils (Sarcophilus harrisii). , 2009, The Journal of animal ecology.

[19]  Alexey I Nesvizhskii,et al.  Comparison of MS(2)-only, MSA, and MS(2)/MS(3) methodologies for phosphopeptide identification. , 2009, Journal of proteome research.

[20]  E. Murchison.  Clonally transmissible cancers in dogs and Tasmanian devils , 2008, Oncogene.

[21]  A. Castor,et al.  Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia , 2008, British journal of haematology.

[22]  B. Viollet,et al.  AMP-activated Protein Kinase Phosphorylates and Desensitizes Smooth Muscle Myosin Light Chain Kinase*♦ , 2008, Journal of Biological Chemistry.

[23]  S. W. Crawley,et al.  Determinants for substrate phosphorylation by Dictyostelium myosin II heavy chain kinases A and B and eukaryotic elongation factor-2 kinase. , 2008, Biochimica et biophysica acta.

[24]  C. Proud,et al.  cdc2–cyclin B regulates eEF2 kinase activity in a cell cycle‐ and amino acid‐dependent manner , 2008, The EMBO journal.

[25]  C. Figdor,et al.  Massive Autophosphorylation of the Ser/Thr-Rich Domain Controls Protein Kinase Activity of TRPM6 and TRPM7 , 2008, PloS one.

[26]  N. Eberle,et al.  Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and duration in 23 cats. , 2008, Journal of veterinary internal medicine.

[27]  Richard D. Smith,et al.  Does trypsin cut before proline? , 2008, Journal of proteome research.

[28]  Katherine Belov,et al.  Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial , 2007, Proceedings of the National Academy of Sciences.

[29]  C. Proud,et al.  PRAS40 Is a Target for Mammalian Target of Rapamycin Complex 1 and Is Required for Signaling Downstream of This Complex* , 2007, Journal of Biological Chemistry.

[30]  M. Hedhammar,et al.  Z(basic)--a novel purification tag for efficient protein recovery. , 2007, Journal of chromatography. A.

[31]  K. Belov,et al.  Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii) , 2007, Immunogenetics.

[32]  D. Levêque,et al.  Molecular Pharmacokinetics of Catharanthus (Vinca) Alkaloids , 2007, Journal of clinical pharmacology.

[33]  C. Proud,et al.  21 Regulation of Translation Elongation and the Cotranslational Protein Targeting Pathway , 2007 .

[34]  P. Mittl,et al.  Sel1-like repeat proteins in signal transduction. , 2007, Cellular signalling.

[35]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[36]  Clare E. Hawkins,et al.  Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrisii , 2006 .

[37]  D. Vertommen,et al.  Insulin Antagonizes Ischemia-induced Thr172 Phosphorylation of AMP-activated Protein Kinase α-Subunits in Heart via Hierarchical Phosphorylation of Ser485/491* , 2006, Journal of Biological Chemistry.

[38]  A. Pearse,et al.  Allograft theory: Transmission of devil facial-tumour disease , 2006, Nature.

[39]  A. Perraud,et al.  The Channel Kinases TRPM6 and TRPM7 Are Functionally Nonredundant* , 2005, Journal of Biological Chemistry.

[40]  Meredith C. Hermosura,et al.  A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Nairn,et al.  Channel Function Is Dissociated from the Intrinsic Kinase Activity and Autophosphorylation of TRPM7/ChaK1* , 2005, Journal of Biological Chemistry.

[42]  W. Kamps,et al.  Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG). , 2005, European journal of cancer.

[43]  I. McGregor,et al.  Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography-ultraviolet absorbance detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[44]  A. Ryazanov,et al.  Alpha-kinases: analysis of the family and comparison with conventional protein kinases. , 2004, Progress in biophysics and molecular biology.

[45]  Wei Li,et al.  Mutations Linked to Leukoencephalopathy with Vanishing White Matter Impair the Function of the Eukaryotic Initiation Factor 2B Complex in Diverse Ways , 2004, Molecular and Cellular Biology.

[46]  Christopher G. Proud,et al.  A Novel mTOR-Regulated Phosphorylation Site in Elongation Factor 2 Kinase Modulates the Activity of the Kinase and Its Binding to Calmodulin , 2004, Molecular and Cellular Biology.

[47]  C. Proud,et al.  Stimulation of the AMP-activated Protein Kinase Leads to Activation of Eukaryotic Elongation Factor 2 Kinase and to Its Phosphorylation at a Novel Site, Serine 398* , 2004, Journal of Biological Chemistry.

[48]  W. Kamps,et al.  Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic Leukemia , 2003, Clinical pharmacology and therapeutics.

[49]  Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. , 2004, Veterinary and comparative oncology.

[50]  D. Vertommen,et al.  Identification of Phosphorylation Sites in AMP-activated Protein Kinase (AMPK) for Upstream AMPK Kinases and Study of Their Roles by Site-directed Mutagenesis* , 2003, Journal of Biological Chemistry.

[51]  M. Herrtage,et al.  Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma. , 2002, The Journal of small animal practice.

[52]  C. Proud,et al.  Regulation of peptide-chain elongation in mammalian cells. , 2002, European journal of biochemistry.

[53]  A. Ryazanov,et al.  Regulation of elongation factor-2 kinase by pH. , 2002, Biochemistry.

[54]  D. Vertommen,et al.  Activation of AMP-Activated Protein Kinase Leads to the Phosphorylation of Elongation Factor 2 and an Inhibition of Protein Synthesis , 2002, Current Biology.

[55]  U. Giger,et al.  Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. , 2002, Journal of the American Veterinary Medical Association.

[56]  Philip R. Cohen,et al.  A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38δ , 2001, The EMBO journal.

[57]  C. Proud,et al.  Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase , 2001, The EMBO journal.

[58]  J Kuriyan,et al.  Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. , 2001, Molecular cell.

[59]  Kathryn S. Lilley,et al.  Phosphorylation of elongation factor-2 kinase on serine 499 by cAMP-dependent protein kinase induces Ca(2+)/calmodulin-independent activity , 2001 .

[60]  K. Lilley,et al.  Phosphorylation of elongation factor-2 kinase on serine 499 by cAMP-dependent protein kinase induces Ca2+/calmodulin-independent activity. , 2001, The Biochemical journal.

[61]  A. Ryazanov,et al.  Mapping the functional domains of elongation factor-2 kinase. , 2000, Biochemistry.

[62]  C. Smythe,et al.  ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK , 1999, Oncogene.

[63]  N. Redpath,et al.  Analysis of the domain structure of elongation factor‐2 kinase by mutagenesis , 1999, FEBS letters.

[64]  A. Ryazanov,et al.  Alpha-kinases: a new class of protein kinases with a novel catalytic domain , 1999, Current Biology.

[65]  W. Kamps,et al.  Vincristine pharmacokinetics after repetitive dosing in children , 1999, Cancer Chemotherapy and Pharmacology.

[66]  G. S. Price,et al.  Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. , 1998, Journal of veterinary internal medicine.

[67]  K. Gelmon,et al.  Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. , 1997, Journal of pharmaceutical and biomedical analysis.

[68]  D. Vertommen,et al.  Phosphorylation and Activation of Heart 6-Phosphofructo-2-kinase by Protein Kinase B and Other Protein Kinases of the Insulin Signaling Cascades* , 1997, The Journal of Biological Chemistry.

[69]  M Wiedmann,et al.  Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Rhoads,et al.  Sequence motifs for calmodulin recognition , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  A. Legendre,et al.  Marked neutropenia in five tumor-bearing cats one week following single-agent vincristine sulfate chemotherapy. , 1996, Veterinary clinical pathology.

[72]  C. Proud,et al.  Regulation of translation elongation factor‐2 by insulin via a rapamycin‐sensitive signalling pathway. , 1996, The EMBO journal.

[73]  S. D. de Graaf,et al.  Vincristine disposition in children with acute lymphoblastic leukemia. , 1995, Medical and pediatric oncology.

[74]  M. Bally,et al.  Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs , 1994, Anti-cancer drugs.

[75]  C. Proud,et al.  Cyclic AMP-dependent protein kinase phosphorylates rabbit reticulocyte elongation factor-2 kinase and induces calcium-independent activity. , 1993, The Biochemical journal.

[76]  C. Proud,et al.  Purification and phosphorylation of elongation factor-2 kinase from rabbit reticulocytes. , 1993, European journal of biochemistry.

[77]  C. Proud,et al.  Identification of the phosphorylation sites in elongation factor‐2 from rabbit reticulocytes , 1991, FEBS letters.

[78]  M. Jordan,et al.  Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.

[79]  L. Ovchinnikov,et al.  Three phosphorylation sites in elongation factor 2 , 1990, FEBS letters.

[80]  P. D. de Jong,et al.  Ligation-independent cloning of PCR products (LIC-PCR). , 1990, Nucleic acids research.

[81]  J. Gariépy,et al.  Dictyostelium myosin II heavy-chain kinase A is activated by autophosphorylation: studies with Dictyostelium myosin II and synthetic peptides. , 1990, Biochemistry.

[82]  O. Nygård,et al.  Functional properties of phosphorylated elongation factor 2. , 1990, European journal of biochemistry.

[83]  A. Ryazanov,et al.  Mechanism of elongation factor 2 (EF‐2) inactivation upon phosphorylation Phosphorylated EF‐2 is unable to catalyze translocation , 1989, FEBS letters.

[84]  A. Nairn,et al.  Identification of the major Mr 100,000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2. , 1987, The Journal of biological chemistry.

[85]  A. Ryazanov.  Ca2+/calmodulin‐dependent phosphorylation of elongation factor 2 , 1987, FEBS letters.

[86]  G. Côté,et al.  Purification and characterization of a myosin heavy chain kinase from Dictyostelium discoideum. , 1987, The Journal of biological chemistry.

[87]  A. Nairn,et al.  Identification of calmodulin-dependent protein kinase III and its major Mr 100,000 substrate in mammalian tissues. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[88]  E. Macewen,et al.  Vincristine for treatment of transmissible venereal tumor in the dog--. , 1982, Journal of the American Veterinary Medical Association.

[89]  D. Morton,et al.  Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids. , 1979, Cancer treatment reports.

[90]  P. Cohen,et al.  The substrate specificity of adenosine 3':5'-cyclic monophosphate-dependent protein kinase of rabbit skeletal muscle. , 1977, The Biochemical journal.

[91]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[92]  D. Love,et al.  Studies on feline lymphosarcoma in the Sydney area. , 1974, The Australian journal of experimental biology and medical science.

[93]  W. Wooster,et al.  Crystal structure of , 2005 .

[94]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[95]  T. Dawson,et al.  Standard metabolism, body temperature, and surface areas of Australian marsupials. , 1970, The American journal of physiology.

[96]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.